Vascular Endothelial Growth Factor Receptor 3 Extracellular Domains 1-3 Fused To A Igg1 Fc Fragment

2 trials

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

0 Recruiting

2 Completed trials

1 Sponsors

17 Countries

Phase III

Phase III: 2

Indications tested

Neovascular age-related macular degeneration 2

Sponsors using this IMP

Opthea Limited 2

All trials

2 total

A clinical study of OPT-302 with ranibizumab compared to ranibizumab alone in patients with neovascular age-related macular degeneration Ended

2024-512879-13-00 Phase III 10 countries Opthea Limited
A clinical study of OPT-302 with aflibercept compared to aflibercept alone in patients with neovascular age-related macular degeneration Ended

2024-512880-30-00 Phase III 16 countries Opthea Limited

Showing 1–2 of 2 trials

← All drugs A–Z